SCHEMBL1314825

SCHEMBL1314825

Cc1cccc(C)c1[SiH](Cl)Cc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.36
ATM Q13315 1/20 0.35
ACHE P22303 2/20 0.35
TSHR P16473 1/20 0.35
TP53 P04637 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
MAPT P10636 3/20 0.34
SCN4A P35499 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
SLC6A2 P23975 2/20 0.33
TAAR1 Q96RJ0 2/20 0.33
SCN8A Q9UQD0 1/20 0.33
MAOA P21397 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1315481 0.85 C5AR1 (0.40) MAPTALDH1A1LMNAL3MBTL1CYP2A6
SCHEMBL1314991 0.79 POLB (0.36) SMN1; SMN2ATMTP53MAPTSCN4A
SCHEMBL1313883 0.72 LMNA (0.36) SMN1; SMN2ATMTSHRMAPTALDH1A1
SCHEMBL1315310 0.72 LMNA (0.37) SMN1; SMN2TSHRMAPTALDH1A1LMNA
SCHEMBL27765573 0.72 SIGMAR1 (0.41) SMN1; SMN2TSHRTP53LOXL2MAPT
SCHEMBL1317183 0.71 POLB (0.39) ATMTP53ALDH1A1LMNA
SCHEMBL1315848 0.71 CYP2C19 (0.37) TSHRLMNATDP1KMT2AMEN1
SCHEMBL3192456 0.69 TP53 (0.43) TSHRTP53LOXL2MAPTALDH1A1
SCHEMBL30515389 0.68 CYP2A6 (0.43) ATMACHETSHRSCN4AALDH1A1
SCHEMBL703495 0.68 CALM1 (0.45) SMN1; SMN2TSHRTP53LOXL2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163950-B2 Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20110275849-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2011-11-10 US disclosed
US-8008521-B2 Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2011-08-30 US disclosed
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2009-03-26 US disclosed
US-7459577-B2 Reacting a chlorosilane with grignard reagent SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-12-02 US disclosed
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275849-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X SMN1; SMN2 4285/4885ATM 2614/4885ACHE 4073/4885
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X SMN1; SMN2 4285/4885ATM 2614/4885ACHE 4073/4885
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes MLX, HAX1, GRIA3 SMN1; SMN2 3661/4885ATM 2845/4885ACHE 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.